Clinical trials
catalyst calendar across sponsors →Studies where PALI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 2 with posted results
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 14.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's DiseaseNCT07428096Safety and tolerability of PALI-2108 administered for 14 days.Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: PALI-2108 | Fibrostenotic Crohn's Disease | 6 | 2026-01-30actual | 2026-02-23 |
| Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.NCT06663605Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PALI-2108, PALI-2108 Placebo | Ulcerative Colitis (UC), Healthy Volunteer | 89 | 2025-07-07actual | 2025-08-07 |
| A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionNCT02836470results2024-06-21Change From Baseline in Extent and Severity of Intra-abdominal Adhesions Among Subjects Treated With LB1148 or PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LB1148, Placebo | Ileus, Post-Operative Adhesions | 112 | 2023-09-06actual | 2024-06-21 |
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel ResectionNCT05470387results2024-06-13Time to Return of Gastrointestinal FunctionRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Company decision | Drug: LB1148, Placebo | Ileus, Gastro-Intestinal Disorder | 23 | 2023-03-06actual | 2024-06-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19